These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Tamargo J; Tamargo M; Caballero R Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808 [TBL] [Abstract][Full Text] [Related]
3. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Teekakirikul P; Zhu W; Huang HC; Fung E Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31888115 [TBL] [Abstract][Full Text] [Related]
5. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Marian AJ Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830 [TBL] [Abstract][Full Text] [Related]
6. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529 [TBL] [Abstract][Full Text] [Related]
7. Mavacamten decreases maximal force and Ca Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957 [TBL] [Abstract][Full Text] [Related]
8. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D; Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100 [TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Zampieri M; Berteotti M; Ferrantini C; Tassetti L; Gabriele M; Tomberli B; Castelli G; Cappelli F; Stefàno P; Marchionni N; Coppini R; Olivotto I Curr Heart Fail Rep; 2021 Aug; 18(4):169-179. PubMed ID: 34148184 [TBL] [Abstract][Full Text] [Related]
10. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217 [TBL] [Abstract][Full Text] [Related]
11. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]
12. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study. Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445 [TBL] [Abstract][Full Text] [Related]
13. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Lombardi R; Rodriguez G; Chen SN; Ripplinger CM; Li W; Chen J; Willerson JT; Betocchi S; Wickline SA; Efimov IR; Marian AJ Circulation; 2009 Mar; 119(10):1398-407. PubMed ID: 19255346 [TBL] [Abstract][Full Text] [Related]
14. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Tower-Rader A; Ramchand J; Nissen SE; Desai MY Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741 [TBL] [Abstract][Full Text] [Related]
15. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study. Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review. Edelberg JM; Sehnert AJ; Mealiffe ME; Del Rio CL; McDowell R Am J Cardiovasc Drugs; 2022 Sep; 22(5):497-510. PubMed ID: 35435607 [TBL] [Abstract][Full Text] [Related]
18. [Mavacamten - the first disease-specific pharmacological treatment of hypertrophic cardiomyopathy]. Magnusson P; Karason K Lakartidningen; 2021 Aug; 118():. PubMed ID: 34498248 [TBL] [Abstract][Full Text] [Related]
19. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Woodland M; Al-Horani RA Cardiovasc Hematol Agents Med Chem; 2023; 21(2):78-83. PubMed ID: 36278454 [TBL] [Abstract][Full Text] [Related]
20. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Dong T; Nissen S; Ospina S; Desai MY Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]